Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus

Journal of the Formosan Medical Association

Volumn 110, Issue 5, 2011, Pages 316-321

  Lin, Hung Pin ^a   Wang, Yi Ping ^a,b,c   Chia, Jean San ^a,b,c   Sun, Andy ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antinuclear antibody; Levamisole; Oral lichen planus

Indexed keywords

ANTINUCLEAR ANTIBODY; LEVAMISOLE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENTAL CLINIC; FEMALE; HUMAN; IMMUNOFLUORESCENCE; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; TAIWAN;

EID: 79960356055     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(11)60047-8     Document Type: Article

References (15)

1. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13: 350-65.
2. Zhao ZZ, Savage NW, Sugerman PB, et al. Mast cell/T cell interactions in oral lichen planus. J Oral Pathol Med 2002; 31:189-95.
3. Khan A, Farah CS, Savage NM, et al. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003;32:77-83.
4. Hirota J, Osaki T, Tatemoto Y. Immunohistochemical staining of infiltrates in oral lichen planus. Path Res Pract 1990; 186:625-32.
5. Yamamoto T, Yoneda K, Ueta E, et al. Cellular immunosuppression in oral lichen planus. J Oral Pathol Med 1990; 19:464-70.
6. Sun A, Chia JS, Chang YF, et al. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 2002;31:196-203.
7. Sun A, Wang JT, Chia JS, et al. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus. Br J Dermatol 2005;152:1187-92.
8. Sun A, Chia JS, Wang JT, et al. Levamisole can reduce the high serum tumor necrosis factor-α level to a normal level in patients with erosive oral lichen planus. Clin Exp Dermatol 2007;32:308-10.
9. Sun A, Chiang CP, Chiou PS, et al. Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. J Oral Pathol Med 1994;23:172-7.
10. Lin SC, Sun A, Wu YC, et al. Presence of anti-basal cell antibodies in oral lichen planus. J Am Acad Dermatol 1992;26:943-7.
11. Lundstrom IM. Serum immunoglobulins and autoantibodies in patients with oral lichen planus. Int J Oral Surg 1985; 14:259-68.
12. Lodi G, Olsen I, Piattelli A, et al. Antibodies to epithelial components in oral lichen planus (OLP) associated with hepatitis C virus (HCV) infection. J Oral Pathol Med 1997; 26:36-9.
13. Carrozzo M, Gandolfo S, Lodi G, et al. Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity. J Oral Pathol Med 1999;28:16-9.
14. Lukac J, Brozovi S, Vucicevi-Boras V, et al. Serum autoantibodies to desmogleins 1 and 3 in patients with oral lichen planus. Croatian Med J 2006;47:53-8.
15. Chang JYF, Chiang CP, Hsiao CK, et al. Significantly higher frequencies of presence of serum autoantibodies in Chinese patients with oral lichen planus. J Oral Pathol Med 2009; 38:48-54.